NASDAQ:BCRX | Free Cash Flow | BIOCRYST PHARMACEUTICALS INC

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2009-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$61.79M
2025-12-31$291.96M
2025-03-31-$27.52M
2024-12-31-$5.21M
2024-03-31-$53.68M
2023-12-31-$8.92M
2023-03-31-$47.51M
2022-12-31-$23.85M
2022-03-31-$77.8M
2021-12-31-$32.46M
2021-03-31-$61.01M
2020-12-31-$42.53M
2020-03-31-$23.28M
2019-12-31-$10.45M
2019-03-31-$27M
2018-12-31-$23.99M
2018-03-31-$19.65M
2017-12-31-$10.52M
2017-03-31-$8.53M
2016-12-31-$5.85M
2016-03-31-$18.84M
2015-12-31-$14.83M
2015-03-31-$3.73M
2014-12-31-$13.89M
2014-03-31-$8.96M
2013-12-31-$4.52M
2013-03-31-$11.2M
2012-12-31-$7.03M
2012-03-31-$12.25M
2011-12-31-$3.98M
2011-03-31-$14.33M
2010-12-31-$5.82M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31$347.37M
2024-12-31-$52.02M
2023-12-31-$95.14M
2022-12-31-$161.85M
2021-12-31-$142.16M
2020-12-31-$135.11M
2019-12-31-$89.58M$343,000.00-$89.93M
2018-12-31-$92.57M$366,000.00-$92.93M
2017-12-31-$41.14M$328,000.00-$41.47M
2016-12-31-$53.44M
2015-12-31-$13.12M
2014-12-31-$38.55M
2013-12-31-$26.53M
2012-12-31-$37.4M
2011-12-31-$32.25M
2010-12-31-$28.56M
2009-12-31-$16.22M